Pharmaceuticals, Biotechnology and Life Sciences
Erytech Pharma today presents poster entitled about A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma, in an event in San Francisco.
Erytech Pharma, the French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, has purchased ordinary shares of the company in a private placement reserved for a specified category of investors (the “Reserved Offering”).
Erytech Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, has reported positive topline results from its Phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA), in combination with chemotherapy for the treatment of second-line metastatic pancreatic cancer.
Erytech Pharma’s new data supporting the second company’s product candidate ERY-MET will be presented at the 2017 Gastrointestinal Cancers Symposium…